Alere Off-Loads Blood Gas Business To Siemens
Executive Summary
Alere is selling its Epocal point-of-care blood diagnostics subsidiary to Siemens Healthineers to comply with US antitrust requirements in advance of its pending acquisition by Abbott. Siemens plans to integrate Epocal's epoc blood analysis system with its digital platforms and its existing point-of-care diagnostics.
You may also be interested in...
Device/Diagnostics Quarterly Deal-Making Statistics, Q3 2017
Third-quarter device financing at $2.38 billion – almost half of that amount from CooperSurgical's $1.1 billion bridge loan – was double the Q2 total, while device acquisitions showed a steep decrease at $3.38 billion versus Q2's $33.4 billion. Diagnostics fundraising also was up in the third quarter, reaching $2.4 billion (a 133% increase over Q2) mostly from Thermo Fisher Scientific's $1.5 billion follow-on offering, which accounted for 63% of the total. In line with the previous quarter's $1.7 billion in M&A, Q3 diagnostics acquisitions had an aggregate value of $1.8 billion, led by Konica Minolta's $1 billion buy of Ambry Genetics.
Alere Unloads Its Triage Assets To Quidel
The deal, subject to the completion of Abbott's planned acquisition of Alere, includes the Triage MeterPro cardiovascular and toxicology businesses, as well as the Triage BNP business. These additions will diversify Quidel's portfolio of rapid diagnostic products for critical care settings and give it a stronger presence in the point-of-care market.
EU Approves Troubled Abbott-Alere Deal – But Abbott Still Wants Out
The European Commission has approved Abbott Laboratories' pending acquisition of Alere, on condition that Alere's Epoc, Triage and BNP businesses are divested to alleviate anti-trust concerns. However, Abbott is still looking to cut loose from the $5.8bn deal.